Purpose: To evaluate clinical, radiographic, and electrophysiological features in the development and prognosis of ischemic post-stroke seizures (PSS). Method: A retrospective study of 1119 patient records was performed between January 2006 and December 2016. After selection, 42 patients with seizures due to ischemic stroke were matched to a control group of 60 patients where seizures were absent. Stroke size and severity were analyzed using ASPECTS and NIHSS, respectively. Hemorrhagic transformation graded by ECASS III classification. Outcomes were assessed using the modified Rankin Scale. Fisher's exact test assessed categorical variables, and Mann-Whitney tested continuous variables. Results: Forty-two patients experienced PSS (22 females; median age 72.5 years) and were matched with 60 control subjects that had ischemic stroke without seizures. Focal seizures were present in 42.9% (18/42), and focal to bilateral convulsions in 57.1% (24/42). Stroke localization and severity did not differ (p = 0.6 and 0.21, respectively). Stroke size in anterior circulation was larger in PSS patients (median ASPECTS 6 vs 8 [p = 0.01]). Posterior circulation stroke size was similar in both groups. The presence of hemorrhage was the primary risk factor for PSS (61.9%) compared to controls (36.7%), p = 0.01. The presence of laminar necrosis (LN) (47.6% vs 21.6%, p = 0.005) and hemosiderin deposition (38.1% vs 18.3%, p = 0.02) were most predictive. PSS patients demonstrated worse outcomes than the controls (median mRS 3 vs 2, [p= < 0.001]) with a median follow up of 14.8 and 20.7 months, respectively. Conclusions: The size of anterior infarction, presence of blood products within the infarct bed, and especially LN predicted PSS.
Introduction
Every year, more than 795,000 people in the United States have a stroke [1] . Stroke is the fifth leading cause of death for Americans [1] . Stroke is a commonly identified cause of epilepsy in patients older than 35 , and the most common cause of seizures in the elderly [2, 3] . From stroke registry data, 5-20% of all patients who have suffered stroke will develop seizures [4] . Frequency is variable due to different study methodologies [4] . In a multicenter, prospective study, seizures occurred in 8.9% of 1897 patients with stroke [4, 5] . Most studies underestimate the frequency of PSS unless continuous electroencephalographic (EEG) monitoring is included. In a retrospective study of acute brain injury, most seizures were electrographic without apparent clinical manifestations [6, 7] .
The presence of seizures in patients with ischemic stroke is associated with increased mortality, longer hospitalization, and greater disability at discharge [8, 9] . Traditionally, post-stroke seizures (PSS) have been classified as early-or late-onset [10, 11] . Early-onset seizures are considered provoked seizures when they are associated with acute ischemic infarction. Authors vary in the definition of PSS including a range of onsets from 1 to 2 weeks following stroke [10] [11] [12] . Late-onset seizures are considered unprovoked seizures that occur from areas of partially injured brain tissue in which neuronal networks have undergone anatomic and physiologic alterations following the stroke [10, 12] .
In this case-control study, we aimed to investigate different electrophysiological, clinical, and radiographic features associated with the development and prognosis of PSS with the prospect of targeting pathology-specific interventions for patients who are at high risk of developing seizures.
Methods

Patient selection
The present study complied with the institutional review boardapproved ethical guidelines of Mayo Clinic (ID: 18-000221). Forty-two patients in this cohort were selected between January 2006 and December 2016 from a group of 158 patients, based on the following criteria: (1) age≥18 years old, (2) ischemic stroke with cortical involvement, (3) new-onset seizures, clinically deemed to be secondary to ischemic stroke, (4) no preceding history of seizures, cerebral amyloid angiopathy, or head trauma, (5) no prior intracranial hemorrhage. A matched pair study design was conducted, with a control group composed of 60 patients from a group of 961 patients who met the above criteria except for the presence of new-onset seizures. ( Fig. 1a and b ).
Clinical variables
Clinical features included patient demographics (age, gender, race), clinical course of stroke and seizures, antiseizure drug (ASD) use, clinical outcomes, EEG tracing and magnetic resonance imaging (MRI) characteristics. Features examined with brain MRI included the presence of LN, microbleeds within the infarct bed, defined as round foci < 5 mm in size [10] , and hemosiderin deposition in the infarct bed. Stroke severity was assessed by using the NIH Stroke Scale, and stroke size was estimated according the Alberta Stroke Program Early CT Score (ASPECTS) for anterior and posterior circulations [13, 14] . Hemorrhagic transformation of ischemic stroke was graded according to the ECASS III classification system regardless of whether or not they received recombinant tissue plasminogen activator (TPA) or thrombectomy. Outcomes were evaluated according to the modified Rankin Scale (mRS) at discharge, 3-months, 1-year, and 2-years follow-up.
A seizure was defined according to the definition set forth by the International League Against Epilepsy (ILAE). The new definition of epilepsy includes patients experiencing a single seizure [15] . Therefore, we chose to avoid terminology that separated a first seizure from epilepsy, though noted it as such when a single event occurred. In line with most other studies [10] [11] [12] 16] , we separated early-onset seizures from late-onset seizures when they occurred within the first week following stroke.
Imaging review
The neuroimaging evaluation was composed of anatomic brain MRI and based on radiological interpretation in addition to a second visual review by the authors using QREADS software (Mayo Clinic). The presence of hemorrhagic transformation was determined on non-contrast brain computed tomography (CT) scans and/or magnetic resonance imaging (MRI). Laminar necrosis (LN) was identified by the presence of high intensity cortical lesions on T1 weighted MRI images following a gyral distribution [17, 18] (Fig. 2a ). Hemosiderin deposition was noted when using susceptibility-weighted (SWI) brain MRI identified by characteristic magnetic field changes [19] (Fig. 2b ).
Statistical analysis
We performed a non-parametric statistical analysis. Continuous variables were reported as median, and categorical variables as frequency in percentages (%). Fisher's exact test and Chi-square test were used to assess categorical variables. The Mann-Whitney test was used to evaluate continuous variables. Statistical significance was considered at p < 0.05. Analysis was performed using GraphPad Prism 7.0 for Microsoft Windows.
Results
Patient characteristics
We enrolled 42 patients after reviewing 158 cases from January 2006 to December 2016 who presented with new-onset seizures due to acute ischemic stroke, and 60 control subjects selected from a population of 961 patients who suffered ischemic stroke involving the cortex without developing seizures. Matching was done based on age, gender, comorbidities, and stroke location. The demographic and clinical characteristics of both groups are shown in Table 1 .
Stroke
The stroke location was noted based on circulation affected (anterior, posterior, both) and hemispheric lateralization (right, left, both). In our cohort, 78.6% (33/42) presented with stroke affecting the anterior circulation, 11.9% (5/42) in the posterior circulation, and 9.5% (3/42) affected both vascular territories. This was not different from the control group where 83.3% (50/60), 13.3% (8/60) and 3.4% (2/60) were involved, respectively (Table 1) . Likewise, the lateralization of stroke in both groups tended to be similar, involving the left hemisphere in 50% (21/42), right hemisphere in 42.9% (18/42), and Table 1 ). The size of stroke evaluated through ASPECTS involving the anterior circulation was significantly higher in patients with PSS (median 6, range 1-9) than the control group (median 8, range 1-9), p = 0.01; however, posterior circulation stroke size was similar in both groups (median 8, range 3-9 vs median 8, range 7-9, p = 0.91). Stroke severity at presentation was assessed with the NIHSS. Severity was greater in PSS patients (median 9, range 1-27) compared to the control group (median 6.5, range 1-32), though did not reach statistical significance (p = 0.21). The rate of TPA administration in both groups also did not differ significantly with group analysis 19.1% [8/42] vs control group 30% [18/60], p = 0.25.
Imaging findings
In our cohort, we identified the presence of hemorrhagic transformation and micro-bleeding in 57.1% (24/42). According to the ECASS III classification, 79.2% (19/24) were Class HI1, 12.5% (3/24) were Class HI2 and PH1, and 8.3% (2/24) were Class 3d [20] . Highly significant findings were the presence of LN in 47.6% (20/42) of the PSS group compared with 21.6% (13/60) in the control group (p = 0.005). The presence of any hemosiderin deposit within the infarct bed was identified in 57.1% (24/42) of our cohort compared with 35% (21/60) in the control group (p = 0.04). LN associated with hemosiderin deposition was present in 30.9% (13/42) of the PSS group compared with 13.3% (8/60) in the control group (p = 0.045).
Seizures
Focal to bilateral convulsive seizures were the most frequent semiology observed in our cohort of patients with PSS, with an incidence of 57.1% (24/42). Focal aware and focal impaired awareness seizures constituted 42.9% (18/42) of the cohort. Traditional scalp EEG was performed in 40 of 42 patients, with continuous EEG monitoring in nearly 50% of the population. Focal electrographic abnormalities including interictal epileptiform discharges or slowing were identified in 60% (24/40) of our cohort. Epileptiform discharges were identified in 25% of our cohort. These appeared within the temporal derivations in 66.7% (16/24) of the cases, frontal in 29.2% (7/24) and parietal in 25% (6/24). Incidence rate of PSS showed a bimodal distribution, with earlyonset seizures (< 1 week) being observed in 33.3% (14/42) of our cohort, with 71.4% (10/14) occurring during the first 24 h, whereas late-onset seizures (> 1 week) were present in 66.7% (28/42) with a mean time of 11.5 months (range 0.36-41 months) ( Fig. 3 ). In our cohort, 28.6% (12/42) presented with new-onset seizures as an isolated episode without recurrence within 1-year follow up with a similar incidence of early and late seizures within this group. Three of 42 patients (7.1%) underwent decompressive hemicraniectomy for stroke and then developed seizures compared with the control group where only 2 of 60 (3.3%) had this management. Patients with LN and/or hemosiderin deposition tended to develop first seizures with a median time of 5 months (range 0.03-41 m) vs 0.1 months (range 0.03-5 m) in patients without them (p = 0.01). Two patients developed status epilepticus and in each case were accompanied by LN and hemosiderin deposits. Sixty-nine percent (29/42) of our cohort was well controlled with levetiracetam monotherapy. Five of 42 patients (11.9%) were resistant to [11] [12] [13] [14] [15] [16] ASDs and LN and/or hemosiderin deposition was present in 80%.
Outcome
Overall, the presence of PSS was associated with worse clinical outcome, according to the median mRs at discharge of 4 (1-5) for our cohort, compared to 2.5 (0-5) in the control group (p = 0.001). We suspect that this was predominately due to the effects of larger stroke size in our cohort (p = 0.01) with PSS as a possible contributor to the worsening of their outcome. The median mRS in patients with PSS was 3 (1-6) at a last median follow up of 14.8 months (0.6-122 m), compared with 2 (0-6) in the control group with a last median follow up of 20.7 months (2-140 m); p= < 0.001 ( Fig. 4) . Of the 42 patients in our cohort, 47.6% (20/42) were categorized as moderate to severely disabled (mRS at last follow-up of 4 or more) and 52.4% (22/42) in the mild disability group (mRS at last follow up of 3 or less). There was a significant association between larger stroke size and poorer clinical outcome. A smaller stroke size was present in patients with PSS demonstrating a better outcome and a median ASPECTS of 8 (4-9) versus 4.5 (1-7) in patients with worse outcome (p= < 0.001). Likewise, patients more severely disabled by stroke were linked to higher NIHSS. Results included NIHSS 5.5 (1-23) as the median value for the group with a favorable outcome and 13.5 for those with a poor outcome (p= < 0.001). Hemosiderin deposition was not a factor in patients experiencing a worse outcome. Nonetheless, LN was present in 70% (14/20) of the moderate to severe disability group vs 27.7% (6/ 22) of patients with mild disability (p = 0.01). Even though detection of epileptiform discharges on the scalp EEG tended to be associated with PSS, they did not portend a worse outcome that was significant (35% [7/20] vs 15% [3/20]; p = 0.27).
Discussion
Ischemic stroke is a leading cause of seizures in adults and the most common cause of seizures after the age of 65 [2] . PSS are a pathological sequela of hypoxic-ischemic brain injury and they can create a state of hyperexcitability in the brain and cause seizures from abnormal excessive depolarization of pooled neurons [21, 22] . Based on studies that have been conducted using animal models, seizures appear to play a key role in the progression of brain injury. Seizures arise from the primary ischemic regions and may involve adjacent regions [10] . PSS have also been found to negatively influence survival in animal models of epilepsy [10] . Therefore, they not only occur as a consequence of hypoxic-ischemic brain injury, but also contribute to worse outcome following hypoxia-ischemia [23] .
Most seizures that occur following stroke are focal-onset seizures. Early and late seizures differ in their underlying mechanisms. There is a lack of consensus for an established division with some using one week to define early seizures and others selecting two weeks [5, [24] [25] [26] . Most consider early seizures as the result from a biochemical imbalance due to acute brain injury, mediated specifically by the excitatory effect of glutamate. Late-onset PSS may result from gliotic scarring after neuronal networks have undergone anatomic and physiologic alterations, making the brain prone to develop seizures [27] . The bimodal distribution for the incidence rate of PSS observed in our study, was comparable with a long-term prospective population-based study in 483 patients with a first ischemic stroke. When seizures occurred, they presented with a higher incidence in the first 24 h with a rapid decline thereafter increasing roughly one year later [28] .
The impact of differentiating late-onset seizure stems from the higher seizure recurrence rate present with seizures that develop after the first week post stroke. Previous studies found recurrent PSS developed in about one-half of patients who experience late seizures, but in less than one-third of patients with early seizures [8, 29] . In our study, we did not find any difference in the recurrence rate or treatment response in either group in contrast with other investigators [8, 29] .
Similar to our results, status epilepticus was found to have an infrequent presentation as a first PSS, constituting less than 10% of all cases [30] .
Several studies report predictive factors associated with development of PSS, in an effort to develop new therapies [8] . In a prospective community-based study with a cohort of 1197 patients with stroke after a period of 7 years, 38 patients (3.2%) developed PSS. The incidence was increased with advanced age, intracerebral hemorrhage, greater lesion size and stroke severity, or when early seizures were present [12] . Similar results were obtained in a prospective study of 1897 patients followed for 9 months with nearly two-fold risk of seizures due to hemorrhagic as opposed to ischemic stroke [10] . Risk factors for seizures after ischemic stroke were cortical location and stroke disability. Late-onset first seizures were an independent risk factor for recurrent seizures after ischemic stroke but not after hemorrhagic stroke [10] . In contrast, we found the risk was no different between early and late seizures. This is relevant when determining when and how long to maintain ASD therapy. Studies have previously shown that cortical infarcts particularly in the middle cerebral artery territory influence the risk of PSS recurrence [31, 32] . This agrees with our results demonstrating a higher incidence of anterior circulation infarcts in patients with PSS.
Recurrent PSS are associated with a higher NIH Stroke Scale scores, greater severity of initial neurologic deficits, and greater disability after stroke [8] . A greater incidence of recurrent PSS has been previously reported to be significantly greater in patients aged < 65 than in patients > 85 years [8] . Cortical involvement alone appears to be a major risk factor for PSS [33] however combined cortical-subcortical strokes may have a higher risk for a first seizure [33] . We found that the extent of stroke using ASPECTS has an association with patients that develop PSS (p = 0.01). Alternatively, we did not find stroke severity to be significant when grading was performed according the NIH Stroke Scale (p = 0.21). We postulate that different metrics involved with assessment may have influenced these conflicting results.
Patients with focal interictal epileptiform discharges and lateralized periodic discharges (LPDs) have a high risk of developing PSS [34] . Focal slowing, diffuse slowing, and normal findings on EEG, on the other hand, have a relatively lower risk [4] . In a previous prospective study of 232 post-stroke patients, EEG performed within 24 h from symptom onset revealed focal or diffuse slowing of background activity in 84% of the cases. Epileptiform abnormalities were present in 16%, with LPDs, a characteristic feature of acute ischemic stroke, accounting for approximately 40% of the latter (6% of the entire cohort of patients) [35] . We found a high prevalence of abnormal focal and diffuse slowing of the EEG background activity in 92.5% (37/40) of patients, with higher incidence of focal temporal abnormalities affecting 40% (16/40) of patients. In addition, epileptiform discharges were present in only one of four patients in our cohort, suggesting a limited predictive value of routine scalp EEG use in patients with PSS. We evaluated continuous EEG monitoring in nearly 50% of our cohort. We did not find a significant difference between the interictal features identified in continuous EEG compared with traditional standard scalp EEG. However, two patients had non-convulsive status epilepticus identified with continuous EEG that were not identified with preceding standard scalp EEG.
Radiographic features identified on neuroimaging studies that have been linked to PSS have included LN and hemosiderin deposits [17, 26, 36] . We also found these features to be risk factors in our casecontrolled series. In contrast to other studies in which blood involving the cerebral cortex was the primary feature associated with PSS, we observed LN to be a highly significant neuroradiological predictor to identify patients who developed PSS (p = 0.005).
Experimentally, intracortical injection of hemoglobin or ferric chloride in rats leads to persistent epileptiform spiking and seizures that occur 2 to 8 days after injection [38, 39] . LN has been correlated with hypoxia, metabolic disturbances, drugs, infections, and status epilepticus [37] . Similarly, we observed a difference in our cases of PSS compared to the group without seizures when hemosiderin deposits were identified (57.1% [24/42] vs 35% [21/60], p = 0.04). This finding agrees with results from previous studies. Unlike LN, hemosiderin deposition was not significantly associated with worsening of long-term outcome (p = 0.99). LN has also been associated with severe focal disabling neurological deficits [17] which we extend to our cohort of patients who experience PSS. We observed the presence of LN in 70% of our population with moderate to severe disability compared to 27.7% in the group of patients with mild disability (p = 0.01) with homogenous size and severity of infarction in both groups (p = 0.58 and 0.48, respectively).
The epileptogenic effect of cortical hemosiderosis has also been identified in other populations of patients besides stroke and epilepsy [38, 39] . In a prospective study of 105 patients with newly diagnosed brain tumor, cortical deposition of hemosiderin was significantly related with the presence of seizures [19, 40] . Patients with resected cavernoma containing hemosiderin deposits have been found to contain neuronal loss, glial proliferation and upregulation of NMDA receptor subunits present to promote seizures [36, 41] .
A subset of ischemic stroke patients who underwent decompressive hemicraniectomy for large middle cerebral infarctions was assessed. Over 1086 days, seizures occurred in 22 of 36 patients (61.1%), demonstrating a very high incidence of PSS in this population [31] . In our study, a small number of patients were operated on and no difference was found between those with and without PSS.
The impact of PSS on stroke outcomes has been investigated in different case series [2, 23, 29] . We observed an important correlation between PSS and both the short-and long-term outcome (p = 0.001 and < 0.001, respectively). This result agrees with those from a large retrospective study at Mayo Clinic, in which 35/489 (7.2%) patients developed first seizures after their first ischemic stroke with a worse functional outcome when measured by the mRs (p = 0.005) [28] . In another prospective study, patients with PSS were younger, had severe strokes, higher admission rate to the intensive care unit, and overall greater morbidity and mortality (p < 0.05) [42] . Other investigations associate PSS with higher mortality, longer hospitalization, and greater disability [27] . It is important for clinicians to be aware of the worse outcome observed in patients with PSS to provide appropriate management and family counseling.
Overall, the risk of death is increased in patients with epilepsy compared to the general population [6] . In patients with PSS, seizures occur in the setting of diffuse vascular disease and therefore have higher mortality rates [3] . The extent to which epilepsy contributes to mortality in this patient group is poorly understood [6] . Two of 42 patients with late PSS in our cohort died within the follow-up study period, suspected to be independent of stroke or seizure due to the presence of several other risk factors. In a prospective study with 109 patients with ischemic stroke (n = 46) and intraparenchymal hemorrhage (n = 63) that underwent continuous EEG monitoring, seizures were associated with cerebral edema producing a midline shift on MRI independent of associated intraparenchymal hemorrhage and predicted worse overall outcome and higher mortality than those without seizures [43] . A large series of 7740 post-stroke patients found a standardized mortality rate of 3.56 [3] . Recurrent seizures were listed as a contributing factor in 14% of deaths [3] . The main cause of death in this population were vascular disorders, though the impact of PSS on mortality was felt to be clinically relevant [3] . In our study, focal to bilateral convulsive seizure was the most frequent semiology. Convulsive seizures are a risk factor for sudden unexpected death in epilepsy and therefore may contribute to an increased mortality in the stroke population. We did not find a treatment effect from the rate of TPA administration between the groups (p = 0.25). Other studies have also not identified a risk for patients to develop PSS following administration of recombinant TPA [44, 45] . Currently, there are no specific evidence-based guidelines for medical management of PSS or strokerelated epilepsy beyond symptomatic treatment with ASDs. The American Heart Association recommends "established management of seizures that may complicate any neurologic illness." [46] A 2014 Cochrane review of ASD therapy in PSS identified a single study but this study examined primary prevention in intracerebral hemorrhage and did not address treatment following seizure onset [11] . A specific treatment of PSS or identification of patients who may benefit from seizure prophylaxis is yet to be recommended. In our cohort, 69% of the patients had good control of seizures with levetiracetam as a monotherapy when seizures occurred. The shift toward the use of levetiracetam instead of phenytoin demonstrates evolution in the treatment of PSS in our series. This reflects more favorable pharmacokinetics and tolerability profiles observed with the newer ASDs such as levetiracetam that have been shown to be safe, effective, and well-tolerated in monotherapy for the elderly population [47] . Although different pathways of epileptogenesis exist for structural-metabolic epilepsies, different etiologies such as patients with PSS may be distinguished due to unique demographic and comorbid medical conditions [47] . Prior studies have found ASDs to be effective in preventing provoked seizures and early PSS, but they are ineffective in preventing unprovoked late seizures and epilepsy [11] . Late-onset first seizures in patients with ischemic stroke involving the cerebral cortex should be treated as epilepsy according to the new definition set forth by the ILAE in 2017 [8] . However, patients with PSS are often elderly and therefore at greater risk of medication side effects and drug-drug interactions [28] . Nonetheless they often represent a special population to have a favorable prognosis for seizure control [48, 49] .
This study has limitations. It was retrospective and therefore suffers from the typical bias seen with this study design as some patients may have been excluded due to missing data. Still, the case-matched control helps strengthen the significance of our observations. In addition, a relatively small number of patients were enrolled. However, most studies have been composed of smaller numbers of patients with PSS extracted from larger databases [3, 28] as was the case in the present series. Another limitation common to all PSS studies is the challenge in identifying all seizures in patients with subclinical, subtle focal seizures, and seizures without awareness where underreporting and under-recognition may have skewed the results to under-represent the prevalence of PSS. In our series, we add new definitions and continuous EEG monitoring to extend results lacking in many of the previous studies [35] .
Conclusion
In our study we identified LN and hemosiderin deposition detected by neuroimaging as significant risk factors for PSS. Seizures were focalonset though manifest as convulsions at treatment in the majority, likely leading to an underestimation of focal seizures as part of the syndrome of PSS. Administration of TPA did not appear to increase the risk nor be a barrier to treatment in our series when seizures appeared early within the first week. With the newer definition of epilepsy encompassing a single seizure [15] , newer ASDs and the increasing use of continuous EEG monitoring, updated large multi-center studies are needed to identify and advance the management of patients with PSS.
